If the biologics license application (BLA) is approved, afami-cel will become the first engineered T-cell therapy for solid tumours and the first effective treatment option for advanced synovial sarcoma in more than a decade, according to the Anglo-American company.
Synovial sarcoma is a rare soft tissue sarcoma, one of around 50 that appear in fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues that can be hard to diagnose and treat.
